Public Profile

Kymab Limited

Kymab Limited, a pioneering biopharmaceutical company headquartered in Great Britain, focuses on the development of innovative therapies for autoimmune diseases and cancer. Founded in 2010, Kymab has made significant strides in the biotechnology sector, particularly with its proprietary antibody platform, which enables the creation of unique monoclonal antibodies. The company’s flagship product, KY1005, is designed to modulate immune responses, showcasing Kymab's commitment to addressing unmet medical needs. With a strong presence in both the UK and the US, Kymab has established itself as a key player in the biopharmaceutical industry, recognised for its cutting-edge research and development capabilities. Notable achievements include successful clinical trials and strategic partnerships that enhance its market position and drive future growth.

DitchCarbon Score

How does Kymab Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

23

Industry Average

Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

4

Industry Benchmark

Kymab Limited's score of 23 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.

82%

Kymab Limited's reported carbon emissions

Kymab Limited, headquartered in Great Britain, currently does not have publicly available carbon emissions data or specific reduction targets. Without emissions figures, it is challenging to assess their carbon footprint or climate commitments. However, the absence of data may indicate that the company is in the early stages of developing its sustainability strategy or reporting framework. As the industry increasingly prioritises climate action, Kymab may be expected to establish clear targets and initiatives in the future to align with global climate goals.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Kymab Limited's primary industry is Research and development services (73), which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. Kymab Limited is headquartered in GB, which has a rank of low, indicating low grid carbon intensity.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Kymab Limited is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
Carbon Disclosure Project
The Climate Pledge
UN Global Compact

Similar Organizations

Crescendo Biologics Limited

GB
Research and development services (73)
Updated 7 days ago

AbCellera

CA
Education services (80)
Updated 7 days ago

Trianni, Inc.

US
Health and social work services (85)
Updated 7 days ago
DitchCarbon Score

RenBio, Inc.

US
Health and social work services (85)
Updated 7 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers